Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

AVVAA World Health Care Products, Inc.

1001 West Loop South, Suite 803
Houston, TX 77027

713-621-6466
www.goldquestcapital.com / info@goldquestcapital.com

SIC: 6162

Quarterly Report

For the Period Ending: February 28, 2026
(the "Reporting Period")

Outstanding Shares
The number of shares outstanding of our Common Stock was:

As of **February 28, 2026,** the number of shares outstanding of our Common Stock was:

966,842,572

As of **May 31, 2025,** the number of shares outstanding of our Common Stock was:

966,442,572

Shell Status
Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: X

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: X

Change in Control
Indicate by check mark whether a Change in Control[4] of the company has occurred during this reporting period:

Yes: ☐ No: X

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

The name of the issuer is AVVAA World Health Care Products, Inc.

The previous name of the issuer was Sierra Gigante Resources until July 2002.

Current State and Date of Incorporation or Registration:

Nevada June 1998 as Sierra Gigante Resources, Inc. The issuer filed an Amendment to the Articles of Incorporation in July 2002 to change the name of the Company to AVVAA World Health Care Products, Inc.

Standing in this jurisdiction: (e.g. active, default, inactive):

Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

None

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

None

List any stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On June 14, 2021, the Custodian filed a Motion to Discharge Custodian with the District Court of Clark County, Nevada. Included with this motion was a resolution and request to cancel 1,012,385,987 shares of common stock issued to former officers, directors, and service providers of the Company. 68,000,000 of these shares were later determined to not be subject to cancellation and were removed from the motion, leaving 944,385,987 shares to be considered by the Court.

On July 8, 2021, prior to the Court ruling on the motion, the Company entered an agreement with a former officer to purchase 565,000,000 *shares owned by the officer and the officer's deceased spouse that were subject to cancellation by the Court. The former officer returned certificates representing 395,000,000 shares, which were officially cancelled by the transfer agent on July 28, 2021. The remaining 170,000,000 shares were still outstanding as of the date of this report.*

On July 15, 2021, the District Court of Clark County, Nevada entered an Order of Final Discharge to discharge the Custodian and cancel 944,385,987 shares of common stock (including the 395,000,000 returned by the former officer). However, the transfer agent was not satisfied with the wording in the court order and refused to cancel the remaining 549,385,987 shares that were covered by the order. These shares were not canceled as of the date of this report.

On September 9, 2021, the Custodian filed a Petition and Motion for Amended Order with the District Court of Clark County, Nevada, to include language satisfactory to the Company's transfer agent for the cancellation of shares without a *physical certificate. On September 10, 2021, the Court approved the amended order. Pursuant to the amended order, 549,385,987 shares were cancelled by the transfer agent on September 22, 2021, with an effective date of September 10, 2021.*

On December 20, *2021, the Company executed* a *purchase agreement with Gold Quest Capital, Inc. Terms of the merger included the issuance of Preferred Series B stock, which has not been completed as of the date of this report*

Address of the issuer's principal executive office:

AVVAA World Health Care Products, Inc.
clo Omnis Public Capital Management LLC
1001 West Loop South, Suite 803
Houston, TX 77027

Address of the issuer's principal place of business:
XX *Check if principal executive office and principal place of business are the same address:*

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: X If Yes, provide additional details below:

On January 25, 2021, the District Court of Clark County, Nevada, case number A20-825998-C, entered an Order Granting Application for Appointment (the "Order') of SSM Monopoly Corporation as Custodian of the Company. Pursuant to the Order, SSM Monopoly Corporation (the "Custodian') has the authority to take any actions on behalf of the Company, that are reasonable, prudent or for the benefit of the Company, including, but not limited to, issuing shares of stock and issuing new classes of stock, as well as entering into contracts on behalf of the Company. In addition, the Custodian, pursuant to the Order, is required to meet the requirements under the Nevada charter.

On July 15, 2021, the District Court of Clark County, Nevada entered a Final Order Granting the Motion to Discharge Custodianship to dismiss the Custodian's authority and control over the Company under the Custodianship. On the same day, Omnis Public Capital Management LLC gained authority and control of the Company through voting rights and the court order.

2) Security Information

Transfer Agent

Name: Legacy Stock Transfer
Phone: 972-612-4120
Email: jason@legacystocktransfer.com
Address: 16801 Addison Road - Suite 247, Addison, TX 75001

Publicly Quoted or Traded Securities:

Trading symbol:	AWH		
Exact title and class of securities outstanding:	Common Stock		
CUSIP:	002432201		
Par or stated value:	0.001		
Total shares authorized:	4,000,000,00	as of date: February 28, 2026	***Other classes of authorized or outstanding equity securities that do not have a trading symbol:***
Total shares outstanding:	966,842,572	as of date: February 28, 2026	
Total number of shareholders of record:	92	as of date: February 28, 2026	

Exact title and class of securities outstanding:	Special 2021 Series A Convertible Preferred Stock
CUSIP	N/A
Par Value	0.001
Total Shares Authorized	1 as of February 28, 2026
Total Shares Issued:	1 as of February 28, 2026

Exact title and class of securities outstanding:	Class A Convertible Super Preferred Stock
CUSIP	N/A
Par Value	0.001
Total Shares Authorized	400,000,000 as of February 28, 2026
Total Shares Issued:	1,250,000 as of February 28, 2026

Exact title and class of securities outstanding:	Class B Convertible Preferred Stock
CUSIP	N/A
Par Value	0.001
Total Shares Authorized	20,000,000 as of February 28, 2026
Total Shares Issued:	17,012,500 as of February 28, 2026

Security Description:

1. **For common equity, describe any dividend, voting and preemption rights.**

One for one voting rights on all common stock, entitled to dividends as determined by the Board of Directors, no Pre-emotive rights.

2. **For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

Special 2021 Series A preferred share *- Each 2021 Series A Preferred stockholder is entitled to 60% of all votes entitled to vote. The share of 2021 Series A Preferred Stock shall convert into common shares at a conversion rate of 1 preferred to 2,000,000,000 common shares. The share of 2021 Series A Preferred Stock shall not be entitled to any dividends and shall not participate in any proceeds available to the corporation's shareholders upon the liquidation, dissolution or winding up of the Corporation.*

Class A Convertible Super Preferred *shall have super voting power (5:1 compared to the company's common stock). Each share is convertible into 2 shares of the company's common stock at the option of the holder after one year. A liquidation preference of 8:1 compared to the company's common stock.*

Series B Preferred shares *are convertible into 100 shares of common stock and do not have any voting rights.*

Stock Dividends and Stock Splits. If the Corporation, at any time while the Series B Preferred Stock is outstanding: (A) shall pay a stock dividend or otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation pursuant to this Series B Preferred Stock), (B) subdivide outstanding shares of Common Stock into a larger number of shares, (C) combine (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (D) issue by reclassification of shares of the Common Stock any shares of capital stock of the Corporation, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding before such event and of which the denominator shall be the number of shares of Common Stock outstanding after such event. Any adjustment made pursuant to this Section shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or reclassification.

whether such assets are capital or surplus, for each share of Series B Preferred Stock an amount equal to the greater of (i) the average price of the Corporation's Common Stock over a period of ten (10) trading days, if the Corporation's Common Stock is listed on a "National Securities Exchange" registered with the SEC under Section 6 of the Securities Exchange Act of 1934 or Over-the-Counter (OTC) securities exchange, or (ii) Two Dollars ($2.00) per share.

3 Describe any other material rights of common or preferred stockholders.

None.

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None.

3) Issuance History

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:
No:[X] Yes: ☐ (If yes, you must complete the table below)

Shares Outstanding - Opening Balance: Date: May 31, 2023 Common: 966,442,572 Preferred: 16,612,501			*Right-click the rows below and select "Insert" to add rows as needed.						
Date of Transaction	**Transaction type (e.g., new issuance, cancellation, shares returned to treasury)**	**Number of Shares Issued (or cancelled)**	**Class of Securities**	**Value of shares issued ($/per share) at Issuance**	**Were the shares issued at a discount to market price at the time of issuance? (Yes/No)**	**Individual/ Entity Shares were issued to. ***You must disclose the control person(s) for any entities listed.**	**Reason for share issuance (e.g. for cash or debt conversion) -OR- Nature of Services Provided**	**Restricted or Unrestricted as of this filing.**	**Exemption or Registration Type.**
10/02/2025	Issuance	325,000	Preferred	.308	No	Terry Obaseki	Cash Sale	Restricted	Sec 144
10/02/2025	Issuance	325,000	Preferred	.308	No	Olusola Oladipo	Cash Sale	Restricted	Sec 144
10/02/2025	Issuance	1,000,000	Preferred	.001	No	Patrick Ashiofu	Cash Sale	Restricted	Sec 144
01/02/2026	Issuance	400,000	Common	.001	No	Adetunji Obawole	Gift	Restricted	Sec 144
Shares Outstanding on Date of This Report: Ending Balance: Date: November 30, 2025 Common: 966,442,572 Preferred: 18,262,501									

B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: X Yes: ☐ (If yes, you must complete the table below)

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations.
Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Gold Quest Capital, Inc. is a Houston, Texas-based real estate lending company that specializes in syndicating first lien, asset-backed real estate mortgages in the residential, commercial, and industrial sectors. The company primarily focuses on asset-backed first lien bridge loans with 12 to 24 month terms, personal guarantees, and loan to values that do not exceed 65%.

B. List any subsidiaries, parent company, or affiliated companies.

None

C. Describe the issuers' principal products or services.

Real estate financing

5) Issuer's Facilities

c/o Omnis Public Capital Management, LLC
1001 West Loop South, Ste 803
Houston, TX 77027

6) All Officers, Directors, and Control Persons of the Company

Names of All Officers, Directors, and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of 5% or more)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
Miguel Sanchez	President, Treasurer, CEO, Director	Houston, TX	1 4,000,000	Special 2021 Series A Prerred Series B Preferred	100% 23.5%	See Below
Omnis Public Capital Mgnt	5% Owner	Houston, TX	865,000	Series B Preferred	5.1%	Miguel Sanchez
Carey Cooley	Secretary/Director	Sugar Land, TX	1,500,000	Series B Preferred	8.8%	
Patrick Ashofu	Director	Houston, TX	5,000,000	Series B Preferred	29.4%	
Luis Beita	Director	Houston, TX	3,000,000	Series B Preferred	17.6%	
Arikit Amin	Director	Houston, TX	1,500,000	Series B Preferred	8.8%	

(1) *Miguel Sanchez owns controlling interest in Omnis Public Capital Management LLC with an address at 1001 West Loop South, Suite 803, Houston, TX 77027. Omnis Public Capital Management LLC owns one (1) share of Special 2021 Series A Preferred Stock, which represents 100% of the issued and outstanding shares. The Special 2021 Series A Preferred Stock collectively have 60% voting rights and each share can be converted into 2,000,000,000 shares of common stock. Omnis Public Capital Management LLC aowns 820,000 shares of the Class B Preferred Shares.*

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

No

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

No

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

No

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

No

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

No

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

N/A

8) Third Party Service Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel
Name: Jonathan D. Leinward
Address 1: 18305 Biscayne Blvd, Suite 200
Address 2: Aventura, FL 33160
Phone: 954-903-7856
Email: jonathan@jdpa.com

Accountant or Auditor

Name: GK Reincke

Firm: Torreon Financial Services, Inc
Address 1: 1390 W Hartley Dr

Address 2: Sahuarita, AZ 85629
Phone: 727 470 8684
Email: factsco@gmail.com

Investor Relations

None

Other Service Providers

None

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: GK Reincke
Title: **Consultant**
Relationship to Issuer: **Consultant**

B. The following financial statements were prepared in accordance with:

☐ IFRS
☒ U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: GK Reincke
Title: **Consultant**
Relationship to Issuer: **Consultant**

Describe the qualifications of the person or persons who prepared the financial statements:

Business entrepreneur, with staff well versed in OTC/SEC reporting

The following financial statements are presented for the recent quarter and year to date:

Balance Sheets for the periods ended February 28, 2026 and May 31, 2025
Statement of Income for the three and nine months ended February 28, 2026 and 2024
Statement of Cash Flows for the three and nine months ended February 28, 2026 and 2024
Statement of Changes in Stockholders' Equity for the period May 31, 2023 through February 28, 2026
Notes to the Financial Statements

10) Issuer Certification

Principal Executive Officer:

I, Miguel Sanchez, certify that:

1.I have reviewed this Annual Disclosure Statement of AWAA World Health Care Products, Inc.

2 Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3.Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

04/13/2026 /s/ Miguel Sanchez

Miguel Sanchez, President/CEO

Principal Financial Officer:

I, Miguel Sanchez, certify that:

1. I have reviewed this Annual Disclosure Statement of AW AA World Health Care Products, Inc.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

04/13/2026 /s/ Miguel Sanchez

Miguel Sanchez, Treasurer

AVVAA World Health Care Products, Inc.
Balance Sheet

ASSETS	February 28, 2026 (Unaudited)	May 31, 2025 (Unaudited)
Current assets		
Cash	$ 192,742	$ 11,819
Receivable - Omnis Capitl	145,000	0
Inventory - for loans	0	221,374
Total current assets	337,742	233,193
Other Assets		
Mortgage receivables	1,060,000	0
Loan fees	10,250	10,000
Total Assets	$ 1,407,992	$ 243,193
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		
Current liabilities		
Accounts payable	$ 17,531	$ 15,964
/Customer deposits	1,778	0
Advances by Shareholder	22,102	18,302
Total current liabilities	41,411	34,266
Investments for Lending	1,251,660	250,000
Total Liabilities	1,293,071	284,266
Stockholders' equity (deficit)		
Preferred Stock - $0.001 par value, 420,000,000 shares authorized: 18,262,501 and 16,612,501 shares outstanding as of February 28, 2026 and May 31, 2025, respectively	18,263	16,613
Common stock, $0.001 par value; , 4,000,000,000 shares authorized, 966,842,572 and 966,442,572 shares outstanding as of February 28, 2026 and May 31, 2025, respectively	966,843	966,443
Additional paid-in capital	25,021,261	24,822,911
Accumulated deficit	(25,891,446)	(25,847,040)
Total stockholders' (deficit)	114,921	(41,073)
Total Liabilities and Stockholders' Equity	$ 1,407,992	$ 243,193

The accompanying Notes to the Financial Statements are an integral part of these statements

AVVAA World Health Care Products, Inc.

Statements of Income
(Unaudited)

	For the Three Months Ended February 28,		For the Nine Months Ended February 28,	
	2026	2025	2026	2025
Mortgage revenues	$ 25,901	$ 0	$ 93,091	$ 0
Cost of Revenues	12,513	0	35,538	0
Gross Profit	13,388	0	57,553	0
Operating Expenses				
General & Administrative	25,172	726	44,001	29,124
Total Operating Expenses	25,172	726	44,001	29,124
Net Operating Income	(11,784)	(726)	13,552	(29,124)
Other Income (Expense)				
Interest expense	(11,185)	(2,168)	(39,037)	(2,678)
Total Other Income (Expense)	(11,185)	(2,168)	(39,037)	(2,678)
NET INCOME	$ (22,969)	$ (2,894)	$ (25,485)	$ (31,802)

The accompanying Notes to the Financial Statements are an integral part of these statements

AVVAA World Health Care Products, INC

Statement of Cash Flows
(Unaudited)

	For the Three Months Ended February 28,		For the Nine Months Ended February 28,	
	2026	2025	2026	2025
Cash flows from operations				
Net (loss)	$ (22,969)	$ (2,894)	$ (25,485)	$ (31,802)
Prior period adjustment	(18,521)	0	(15,387)	0
Adjustments to reconcile Net income to operations				
Decrease in Inventory for loans	20,749	0	221,374	
Increase in Receivable - Omnis Capital	0		(145,000)	
Loan fees	(250)		(250)	
Decrease in Accounts Payable	14,639	240	(1,567)	10,361
Increase in Loan fees payable	1,778		1,778	
Accrued interest	0	2,027	0	2,027
Increase in Shareholder Advances	3,800	0	3,800	7,997
Net cash provided by(used) operating activities	(774)	(627)	39,263	(11,417)
Cash flows from investing activities	0	0	0	0
Net cash provided (used) by investing activities	0	0	0	0
Cash flows from financing activities				
Increase in Mortgage Receivable	0	0	(1,060,000)	0
Sale of Preferred Stock	0	0	200,000	0
Loan proceeds borrowed	179,260	0	1,001,660	0
Net cash provided (used) by financing activities	179,260	0	141,660	0
Net Increase (Decrease) in cash	178,486	(627)	180,923	(11,417)
Cash, Beginning of Period	14,256	2,003	11,819	12,793
Cash, End of Period	$ 192,742	$ 1,376	$ 192,742	$ 1,376

The accompanying Notes to the Financial Statements are an integral part of these statements

AVVAA World Health Care Products Inc

Statement of Shareholder's Equity

	Common Stock		Special 2021 Series A Preferred Stock		Series B Preferred Stock		Additional Paid in	Accumulated	Total Stockholder's
	Shares	Par Value	Shares	Par Value	Shares	Par Value	Capital	Deficit	Equity
Balance - May 31, 2023	966,442,572	$ 966,443	1,250,000	$ 1,250	15,362,501	$ 15,363	$ 24,827,911	$ (25,765,199)	$ 45,767
Rounding								(1)	0
Net Profit or Loss								(42,751)	(42,751)
Balance - May 31, 2024	966,442,572	$ 966,443	1,250,000	$ 1,250	15,362,501	$ 15,363	$ 24,827,911	$ (25,807,951)	$ 3,016
Prior period adj							(5,000)	34	(4,966)
Net Profit or Loss								(39,123)	(39,123)
Balance - May 31, 2025	966,442,572	$ 966,443	1,250,000	$ 1,250	15,362,501	$ 15,363	$ 24,822,911	$ (25,847,040)	$ (41,073)
Stock issuance	400,000	400							400
Prior period adjustment								(18,921)	
Preferred Stock - Cash sale					1,650,000	1,650	198,350		200,000
Net Profit or Loss								(25,485)	(25,485)
Balance - February 28, 2026	966,842,572	$ 966,843	1,250,000	$ 1,250	17,012,501	$ 17,013	$ 25,021,261	$ (25,891,446)	$ 133,842

The accompanying Notes to the Financial Statements are an integral part of these statements

AVVAA WORLD HEALTH CARE PRODUCTS, INC.
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

February 28, 2026
(Unaudited)

NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS

AVVAA World Health Care Products, Inc. (the "Company", "we", "us" or "our"), a Nevada corporation, has a fiscal year end of May 31 and is listed on the OTC Pink Markets under the trading symbol AVVH. The Company had ceased operations but not taken steps to dissolve, liquidate and distribute its assets. The Company was incorporated on June 3, 1998 in the State of Nevada as Sierra Gigante Resources, Inc.

In June 2002, the Company completed the acquisition of I 00% of the common shares of Mind Your Own Skin Products Inc. ("MYOSP"), a company incorporated under the Company Act of the Province of British Columbia, Canada. This share issuance resulted in a reverse takeover of the Company by the shareholders of MYOSP. Certain directors and officers of MYOSP became directors and officers of the Company.

In July 2002, the Company filed an Amendment to the Articles of incorporation to change its name to AVVAA World Health Care Products, Inc. The Company's primary business was the distribution and sale of over the counter all-natural therapeutic skin care products designed to treat the symptoms of skin diseases such as eczema, psoriasis, and acne.

Required reporting requirements with the Nevada Secretary of State, the failure to hold an Quarterly meeting of stockholders and pay its Quarterly franchise tax from 2014 to 2020 resulted in its Nevada charter being revoked. The Company also did not provide adequate current public information as defined in Rule 144, promulgated under the Securities Act of 1933, and was thus subject to revocation by the Securities and Exchange Commission pursuant to Section 12(k) of the Exchange Act.

On November 5, 2020, SSM Monopoly Corporation, a shareholder of the Company, made a demand to the Company, at last address of record, to comply with the Nevada Secretary of State statues N.R.S. 78.710 and N.R.S. 78.150. On December 8, 2020, a petition was filed against the Company in the District Court of Clark County, Nevada, entitled "In the Matter of AVVAA World Health Care Products, Inc., a Nevada corporation" under case number A-20-825998- C by SSM Monopoly Corporation, along with an Application for Appointment of Custodian, after several attempts to locate prior management and reinstate the Company's Nevada charter, which had been revoked. The District Court, Clark County, Nevada and was appointed as the custodian of the Company in January 2021.

On January 25, 2021, the District Court of Clark County, Nevada entered an Order Granting Application for Appointment of SSM Monopoly Corporation (the "Order"), as Custodian of the Company. Pursuant to the Order, the SSM Monopoly Corporation (the "Custodian") has the authority to take any actions on behalf of the Company, that are reasonable, prudent or for the benefit of pursuant to, including, but not limited to, issuing shares of stock and issuing new classes of stock, as well as entering in contracts on behalf of the Company.

Also, on January 25, 2021, the Custodian granted itself, one share of preferred stock, Special 2021 Series A Preferred Stock ("2021 Series A Preferred") at par value of $0.001. The 2021 Series A Preferred has 60% voting rights over all classes of stock and convertible into 2,000,000,000 shares of the Company's common stock.

Also on January 25, 2021, the Custodian appointed Kareem Mansour as the Company's sole officer and director.

On January 27, 2021, in a private transaction, the Custodian entered into a Securities Purchase Agreement (the "SPA") with Krisa Management LLC, a Texas limited liability company, to sell the 2021 Series A Preferred. Upon closing of the SPA on January 27, 2001, Krisa Management LLC acquired 60% control of the Company Also on January 27, 2021, the Custodian appointed Carey W. Cooley as the Company's sole officer and director. On January 27, 2021, Kareem Mansour resigned as an officer and director of the Company.

On February 5, 2021, the Company filed a Certificate of Revival with the Secretary State of the State of Nevada, which

reinstated the Company's charter and appointed a new Resident Agent in Nevada.

On April 12, 2021, at a Specially Called Meeting of all of the Officers and Directors of the Company, a resolution was ratified and adopted canceling 1,012,385,987 shares of common stock issued by previous management after a Cease Trade Order issued by the British Columbia Securities Commission had gone into effect in Canada on October I, 2009. The Court Appointed Custodian also ratified and adopted a resolution canceling certain shares as in the best interest of the Corporation.

On April 26, 2021, in a private transaction, Krisa Management LLC entered into a Securities Purchase Agreement (the "SPA") with Omnis Public Capital Management LLC, a Texas limited liability company, to sell the 2021 Series A Preferred. Upon closing of the SPA on May 3, 200I, Omnis Public Capital Management LLC acquired 60% control of the Company.

On June 14, 2021, the Custodian filed a Motion to Discharge Custodian (the "Motion") in the District Court of Clark County, Nevada. On July I, 2021, the Motion was amended to remove 68,000,000 shares from the resolution canceling shares, leaving 944,385,987 shares of common stock to be canceled.

On July 8, 2021, prior to the Court ruling on the Motion to Discharge, the Custodian entered into an Agreement with a shareholder (the "Shareholder") to purchase back some of the shares covered by the resolution to cancel shares. Pursuant to the Agreement, 565,000,000 shares of common stock beneficially owned by the Shareholder were purchased back for $30,000. On July 28, 2021, certificates for 395,000,000 of these shares were canceled by the Company upon return. The certificates for the other 170,000,000 of these shares were lost and were awaiting additional documentation from the Shareholder.

On July 15, 2021, the District Court of Clark County, Nevada entered a Final Order Granting the Motion to Discharge Custodianship to accept all actions taken by the Custodian (including the cancellation of 944,385,987 shares of common stock) and to dismiss the Custodian's authority and control over the Company under the Custodianship. On the same day, Omnis Public Capital Management LLC gained authority and control of the Company through voting rights and the court order.

On September 9, 2021, the Custodian filed a Petition and Motion for Amended Order with the District Court of Clark County, Nevada, to include language satisfactory to the Company's transfer agent for the cancellation of shares without a physical certificate. On September 10, 2021, the Cort approved the amended order. Pursuant to the amended order, 549,385,987 shares were cancelled by the transfer agent on September 22, 2021, with an effective date of September I 0, 2021.

On December 20, 2021, the Company executed a purchaser agreement with GoldQuest Capital, Inc

The company is currently operating as a capital financing company for real estate borrowings.

NOTE 2 - BASIS OF PRESENTATION AND GOING CONCERN

Basis o(Presentation

The Company has earned only limited revenues from principal operations. Accordingly, the Company's activities have been accounted for as those of a "Development Stage Enterprise" as set forth in Financial Accounting Standards Board Statement No. 7 ("SFAS 7"). Among the disclosures required by SFAS 7 are that the Company's financial statements be identified as those of a development stage company, and that the statements of operations, stockholders' equity (deficit) and cash flows disclose activity since the date of the Company's inception.

Basis o(Accounting

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States. All intercompany transactions have been eliminated.

Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company currently has an accumulated deficit of $ 25,801,811 as of February 28, 2026. The Company intends to continue operations as set out below and raise the necessary funds to carry out the aforementioned strategies. The Company cannot be certain that it will be successful in these strategies even with the required funding.

These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

For purposes of the statement of cash flows, cash equivalents include demand deposits, money market funds, and all highly liquid debt instructions with original maturities of three months or less.

Financial Instruments

The FASB issued ASC 820-10, *Fair Value Measurements and Disclosures,* for financial assets and liabilities. ASC 820-10 provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. ASC 820-10 defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

Level I: Quoted prices in active markets for identical assets or liabilities

Level 2: Observable inputs other than Level I prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Concentrations and Credit Risks

The Company's financial instruments that are exposed to concentrations and credit risk primarily consist of its cash, sales and accounts receivable. The Company places its cash and cash equivalents with financial institutions of high credit w01ihiness. At times, its cash and cash equivalents with a particular financial institution may exceed any applicable government insurance limits. The Company's management plans to assess the financial strength and credit wo1ihiness of any parties to which it extends funds, and as such, it believes that any associated credit risk exposures are limited.

Foreign Currency Translation

The accounts of the Company are accounted for in accordance with the Statement of Financial Accounting Statements No. 52 ("SFAS 52"), "Foreign Currency Translation". The financial statements of the Company are translated into

US dollars as follows: assets and liabilities at year-end exchange rates; income, expenses and cash flows at average exchange rates; and shareholders' equity at historical exchange rate.

Monetary assets and liabilities, and the related revenue, expense, gain and loss accounts, of the Company are re-measured at year-end exchange rates. Non-monetary assets and liabilities, and the related revenue, expense, gain and loss accounts are re-measured at historical rates. Adjustments which result from the re-measurement of the assets and liabilities of the Company are included in net income.

Share-Based Compensation

ASC 718, *Compensation - Stock Compensation,* prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized in the period of grant.

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, *Equity - Based Payments to Non-Employees.* Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction 1s determined at the earlier of performance commitment date or performance completion date.

As of February 28, 2025 and 2024, respectively, there was $Nil of unrecognized expense related to non-vested stock-based compensation arrangements granted. There have been no options granted during the three months ended February 28, 2025 and 2023, respectively.

Income Taxes

The Company accounts for income taxes under ASC 740, *Income Taxes.* Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Deferred tax assets or liabilities were offset by a 100% valuation allowance, therefore there has been no recognized benefit as of February 28, 2026 and 2025, respectively. Further it is unlikely with the change of control that the Company will have the ability to realize any

future tax benefits that may exist.

Commitments and Contingencies

The Company follows ASC 450-20, *Loss Contingencies,* to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

Earnings Per Share

Net income (loss) per share is calculated in accordance with ASC 260, *Earnings Per Share.* The weighted-average number of common shares outstanding during each period is used to compute basic earnings or loss per share. Diluted earnings or loss per share is computed using the weighted average number of shares and diluted potential common shares outstanding. Dilutive potential common shares are additional common shares assumed to be exercised.

Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding at February 28, 2026 and 2025. Due to net operating loss, there is no presentation of dilutive earnings per share, as it would be anti-dilutive.

Forgiveness of Indebtedness

The Company follows the guidance of AS 470.10 related to debt forgiveness and extinguishment. Debts of the Company are considered extinguished when the statute of limitations in the applicable jurisdiction expires or when terminated by judicial authority such as the granting of a declaratory judgment. Debts to related parties or shareholders are treated as capital transactions when forgiven or extinguished and credited to additional paid in capital. Debts to non-related parties are treated as other income when forgiven or extinguished.

NOTE 4 - INCOME TAXES

Income taxes are provided based upon the liability method. Under this approach, deferred income taxes are recorded to reflect the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year-end. A valuation allowance is recorded against deferred tax assets if management does not believe the Company has met the "more likely than not" standard imposed by accounting standards to allow recognition of such an asset.

As of February 28, 2026, the Company expected no net deferred tax assets to be recognized, resulting from net operating loss carry forwards. Deferred tax assets were offset by a corresponding allowance of 100%.

The Company experienced a change in control during the year, and therefore no more than an insignificant portion of this net operating allowance will ever be used against future taxable income.

NOTE 5 - NOTES PAYABLE - RELATED PARTIES

The Company has no Notes Payable to Related Parties, however, as of February 28, 2026 and May 31, 2025, shareholders had advanced a total of $ 22,102 and $18,302, respectively.

NOTE 6 - NOTES PAYABLE

During the year ended May 31, 2025, the Company received two loans for $150,000 and $100,000 to be used as starting capital for its lending operations. During the nine month ended February 28, 2026, the Company has increased this total

of $ 1,001660 for a total payable of $1,251,660, The notes carry an interest rate of 8% which accrues on a daily basis.

NOTE 7 - COMMITMENTS AND CONTINGENCIES

Risks and Uncertainties

The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure.

Legal and other matters

In the normal course of business, the Company may become a party to litigation matters involving claims against the Company. The Company's management is unaware of any pending or threatened assertions and there are no current matters that would have a material effect on the Company's financial position or results of operations.

NOTE 8 - SUBSEQUENT EVENTS

Management has evaluated subsequent events through the date of preparation of the consolidated financial statements, the date the consolidated financial statements were available to be issued. Management is not aware of any significant events that occurred subsequent to the balance sheet date that would have a material effect on the consolidated financial statements thereby requiring adjustment or disclosure.

As of February 28, 2026, there were no significant changes or events that would require disclosure.